NDA Submitted for Vismodegib for Basal Cell Carcinoma - MPR
Links shared publicly online about this topic.
- 3total visits
NDA Submitted for Vismodegib for Basal Cell Carcinoma - MPR
empr.com —
Curis, Inc. and its collaborator Genentech, announced the submission of a new drug application (NDA) for vismodegib for the treatment of patients with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
View full resource at empr.com
Tags: Cancer, Skin Cancer, Basal Cell Carcinoma, Drug, Genentech, Surgery
Most Recently Shared on September 13, 2011 at 8:30 pm By:
NDA Submitted for Vismodegib for Basal Cell Carcinoma http://ow.ly/6tm9I #oncology
Genentech: Newsroom: Press Releases: News Release September 12, 2011
gene.com — “Genentech: Newsroom: Press Releases: News Release September 12, 2011” View full resource at gene.com
Most Recently Shared on September 12, 2011 at 11:01 am By:
GNE submits new drug application to FDA for advanced basal cell carcinoma, a rare skin cancer http://t.co/G0OwlRe
Advertisement
